TTY Biopharm Co Ltd - Asset Resilience Ratio
TTY Biopharm Co Ltd (4105) has an Asset Resilience Ratio of 4.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4105 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how TTY Biopharm Co Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of TTY Biopharm Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down TTY Biopharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TTY Biopharm Co Ltd (4105) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$467.74 Million | 4.12% |
| Total Liquid Assets | NT$467.74 Million | 4.12% |
Asset Resilience Insights
- Limited Liquidity: TTY Biopharm Co Ltd maintains only 4.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
TTY Biopharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare TTY Biopharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Dermapharm Holding SE
XETRA:DMP |
Drug Manufacturers - Specialty & Generic | 1.23% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
|
Daewoong Pharma
KO:069620 |
Drug Manufacturers - Specialty & Generic | 0.19% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
Annual Asset Resilience Ratio for TTY Biopharm Co Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for TTY Biopharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.12% | NT$467.74 Million ≈ $14.74 Million |
NT$11.35 Billion ≈ $357.53 Million |
+1.28pp |
| 2024-12-31 | 2.84% | NT$309.01 Million ≈ $9.74 Million |
NT$10.86 Billion ≈ $342.24 Million |
+0.86pp |
| 2023-12-31 | 1.98% | NT$195.54 Million ≈ $6.16 Million |
NT$9.87 Billion ≈ $311.11 Million |
-1.42pp |
| 2022-12-31 | 3.40% | NT$326.86 Million ≈ $10.30 Million |
NT$9.60 Billion ≈ $302.47 Million |
-0.60pp |
| 2021-12-31 | 4.01% | NT$372.65 Million ≈ $11.74 Million |
NT$9.30 Billion ≈ $292.89 Million |
+0.35pp |
| 2020-12-31 | 3.66% | NT$342.40 Million ≈ $10.79 Million |
NT$9.36 Billion ≈ $294.92 Million |
-1.39pp |
| 2019-12-31 | 5.05% | NT$482.62 Million ≈ $15.21 Million |
NT$9.55 Billion ≈ $300.96 Million |
-0.81pp |
| 2018-12-31 | 5.86% | NT$530.83 Million ≈ $16.72 Million |
NT$9.05 Billion ≈ $285.22 Million |
-12.77pp |
| 2017-12-31 | 18.64% | NT$1.77 Billion ≈ $55.82 Million |
NT$9.51 Billion ≈ $299.52 Million |
-- |
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more